Rise in Telemedicine Tied to Modest Decrease in Low-Value, Point-of-Care Testing

Follow Drugslib on

Medically reviewed by Carmen Pope, BPharm. Last updated on March 4, 2025.

By Lori Solomon HealthDay Reporter

TUESDAY, March 4, 2025 -- Telemedicine adoption is associated with modestly lower use of low-value, point-of-care testing among Medicare beneficiaries, according to a study published online Feb. 24 in JAMA Internal Medicine.

Ishani Ganguli, M.D., from Harvard Medical School and Brigham and Women's Hospital in Boston, and colleagues sought to quantify the association between telemedicine adoption and low-value testing among fee-for-service Medicare beneficiaries. Beneficiary-level linear regression in a difference-in-differences (DiD) analysis included a sample of 1.38 million Medicare beneficiaries who were attributed to high-telemedicine systems and 999,051 beneficiaries who were attributed to low-telemedicine systems.

The researchers found that from 2019 to 2022, those in high-telemedicine systems had a small differential rise in visits (DiD visits per beneficiary, 0.12) and differential decreases in the use of seven of 20 low-value tests (mostly point of care): cervical cancer screening (DiD, −0.45 percentage points [pp]), screening electrocardiograms (DiD, −1.30 pp), screening metabolic panels (DiD, −1.84 pp), preoperative complete blood cell counts (DiD, −0.64 pp), preoperative metabolic panels (DiD, −1.35 pp), total or free triiodothyronine level testing for hypothyroidism (DiD, −0.90 pp), and imaging for uncomplicated low back pain (DiD, −1.66 pp). Additionally, patients in high-telemedicine systems saw statistically significant differential decreases in spending on visits per beneficiary (−$47.87) and on two of 20 low-value tests, although there were no differences in low-value spending overall.

"Results suggest possible benefits of telemedicine and mitigate concerns about telemedicine contributing to increased spending," the authors write.

Two authors disclosed ties to the health care and technology industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2025-03-05 06:00

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords